Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

Novo Nordisk A/S (NYSE:NVO) has reportedly launched its weight-loss drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:LLY).

In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the second-largest population of overweight or obese people by 2050.

A Reuters report on Tuesday said that Wegovy, a weekly injection, will be available in pharmacies by the end of this month. It could take some market share away from Eli Lilly. Meanwhile, sales of Eli Lilly's drug Mounjaro rose 60% between April and May, the report highlighted, citing industry analysts.

Also Read: Novo Nordisk’s Weight Loss Injection CagriSema Data Sparks Investor Concern

Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, ...